| 标题 |
Atorvastatin safety and pharmacokinetics in acute kawasaki disease patients with coronary artery abnormalities
阿托伐他汀在急性川崎病冠状动脉异常患者中的安全性和药代动力学
|
| 网址 |
求助人暂未提供
|
| DOI |
暂未提供，该求助的时间将会延长，查看原因？
|
| 其它 | Introduction: Despite therapy with intravenous immunoglobulin, 25% of children with Kawasaki disease (KD) develop coronary artery abnormalities (CAA) and endothelial cell (EC) dysfunction. Based on the pleiotropic effects of statins on restoring EC homeostasis, we performed a Phase I clinical trial of atorvastatin for acute KD patients with early CAA. Hypothesis: A sixweek (wk) course of atorvastatin in acute KD patients (pts) with CAA will be safe, welltolerated and restore EC homeostasis. Methods: This twocenter, Phase I, open label, dose escalation trial enrolled acute KD subjects aged 217 years with an initial CA Z score ≥ 2.5 in a 6wk study of atorvastatin (0.125, 0.25, 0.5 and 0.75 mg/kg/day). Demographic, clinical and laboratory data, and echo core lab readings were collected at baseline, |
| 求助人 | |
| 下载 |
PDF的下载单位、IP信息已删除
浮游
Momomo
浮浮世世
GingerF
小愿张
Huzhu
YifanWang
大龙哥886
遇上就这样吧
从容芮
小伙子
kentonchow
不配.
不安青牛
Vickicherry
谢绍博
无极微光
Yini
风清扬
嘻嘻哈哈
尊敬代桃
维奈克拉
18635986106
xxfsx
皖公网安备34019202002308
